Fears Of Recession Mount As Coronavirus Declared A Pandemic
Biopharma Determined To Maintain Clinical Trials, Drug Launches
Investor sentiment still backing growth for pharma and biotech sectors, but the length and severity of COVID-19's impact globally has yet to be seen.
You may also be interested in...
Funded by the US government since March 2018, the Vancouver-based company aims to have an antibody therapy ready for clinical trials within four months.
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.